US5167616A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Iontophoretic delivery method
Assignee: Alza Corp
•
Filing: 1989-12-14
•
Granted: 1992-12-01
•
Expires: 2009-12-14
Abstract
Abstract An improved method for delivering a drug or beneficial agent transdermally to humans by iontophoresis is provided. The method includes selecting and iontophoretically delivering the drug through a skin site which optimizes the transdermal delivery rate of the drug while minimizing inter-patient variability in skin resistance.
Inventors
- 👤 Ronald P. Haak
- 👤 J. Richard Gyory
- 👤 Jane Yieh
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 17:54
CPC Classifications
A; A61; A61N; A61N1/00; A61N1/02; A61N1/04; A61N1/0404; A61N1/0408; A61N1/0428; A61K; A61K9/00; A61K9/0002; A61K9/0009
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
122 words
A method of optimizing the transdermal flux of a beneficial agent from an iontophoretic agent delivery device through intact human skin and decreasing inter-patient skin resistance variability, comprising: selecting a skin site on intact back skin of the human; placing the iontophoretic delivery device in agent transmitting relation with the intact back skin site, the delivery device contacting the back skin site over an area of about 1 to 200 cm 2 ; and iontophoretically delivering the agent through the back skin at a pharmaceutically effective rate, at an optimized transdermal flux compared to human skin sites other than back skin and at a transdermal flux which exhibits decreased inter-patient skin resistance variability compared to human skin sites other than back skin.
Claim 2
Independent Claim
122 words
A method of optimizing the transdermal flux of a beneficial agent from an iontophoretic agent delivery device through intact human skin and decreasing inter-patient skin resistance variability, comprising: selecting a skin site on intact back skin of the human; placing the iontophoretic delivery device in agent transmitting relation with the intact back skin site, the delivery device contacting the back skin site over an area of about 1 to 200 cm 2 ; and iontophoretically delivering the agent through the back skin at a pharmaceutically effective rate, at an optimized transdermal flux compared to human skin sites other than back skin and at a transdermal flux which exhibits decreased inter-patient skin resistance variability compared to human skin sites other than back skin.
Claim 3
Dependent Claim
83 words
The method of claim 1, wherein the device includes a donor electrode assembly containing the beneficial agent and a return electrode assembly containing an electrolyte, and the method of placing the delivery device in agent transmitting relation with the back skin site includes (i) placing the donor electrode assembly in agent transmitting relation with the intact back skin site and (ii) placing the return electrode assembly in electrolyte transmitting relation with a skin site spaced apart from the selected intact back skin site.
Claim 4
Dependent Claim
28 words
The method of claim 2, wherein the method of placing the delivery device includes adhering the donor electrode assembly to the back skin site using an ion-conducting adhesive.
Claim 5
Dependent Claim
69 words
The method of claim 1, wherein the method of placing the delivery device in agent transmitting relation with the back skin site includes placing a donor electrode assembly containing the beneficial agent on the intact back skin site, placing a return electrode assembly on a skin site spaced apart from the intact back skin site and electrically connecting an electrical power source to the donor and return electrode assemblies.
Claim 6
Dependent Claim
53 words
The method of claim 4, including placing the donor electrode assembly in agent transmitting relation with a first intact back skin site and placing the return electrode assembly in electrolyte transmitting relation with a second intact back skin site, he second back skin site being spaced apart from the first back skin site.
Claim 7
Dependent Claim
13 words
The method of claim 4, including fixing the voltage of the power source.
Claim 8
Dependent Claim
19 words
The method of claim 6, wherein the voltage is fixed in the range of about 1 to 10 volts.
Claim 9
Dependent Claim
12 words
The method of claim 1, wherein the beneficial agent is a drug.
Claim 10
Dependent Claim
31 words
The method of claim 1, wherein the beneficial agent is selected from the group consisting of peptides, polypeptides, proteins and macromolecules having a molecular weight of a least about 300 daltons.
Claim 11
Dependent Claim
42 words
The method of claim 1, wherein the beneficial agent is selected from the group consisting of insulin, growth hormones, buserelin, leuprolide, LHRH, metoclopramide, fentanyl, lidocaine, ketoprofen, sufentanil, terbutaline, droperidol, heparin, interferon, scopolamine, testosterone, gonadorelin, ciclopirox olamine, buspirone, calcitonin, cromolyn sodium, and midazolam.
Claim 12
Independent Claim
166 words
A method of optimizing transdermal flux of a beneficial agent from an iontophoretic delivery device to a human patient, comprising: (a) selecting a skin site on intact back skin of the human patient, (b) placing a donor electrode assembly, which assembly contains a beneficial agent, in agent transmitting relation with the selected intact back skin site, the donor electrode assembly contacting the back skin site over an area of about 0.5 to 100 cm 2 , (c) placing a counter electrode assembly, which assembly contains an electrolyte, in electrolyte transmitting relation with a skin site spaced apart from the selected intact back skin site, (d) connecting an electric power source to the donor and counter electrode assemblies, and (e) iontophoretically delivering the agent through the back skin at a harmaceutically effective rate, at an optimized transdermal flux compared to human skin sites other than back skin, and at a transdermal flux which exhibits decreased inter-patient skin resistance compared to human skin sites other than back skin.
Claim 13
Independent Claim
166 words
A method of optimizing transdermal flux of a beneficial agent from an iontophoretic delivery device to a human patient, comprising: (a) selecting a skin site on intact back skin of the human patient, (b) placing a donor electrode assembly, which assembly contains a beneficial agent, in agent transmitting relation with the selected intact back skin site, the donor electrode assembly contacting the back skin site over an area of about 0.5 to 100 cm 2 , (c) placing a counter electrode assembly, which assembly contains an electrolyte, in electrolyte transmitting relation with a skin site spaced apart from the selected intact back skin site, (d) connecting an electric power source to the donor and counter electrode assemblies, and (e) iontophoretically delivering the agent through the back skin at a harmaceutically effective rate, at an optimized transdermal flux compared to human skin sites other than back skin, and at a transdermal flux which exhibits decreased inter-patient skin resistance compared to human skin sites other than back skin.
Claim 14
Dependent Claim
22 words
The method of claim 1 or 11, including co-delivering the beneficial agent with a skin permeation enhancer through the intact back skin.
Claim 15
Dependent Claim
24 words
The method of claim 11, wherein the power source comprises a battery having a voltage in the range of about 1 to 10 volts.
Claim 16
Dependent Claim
12 words
The method of claim 11, wherein the beneficial agent is a drug.
Claim 17
Dependent Claim
31 words
The method of claim 11, wherein the beneficial agent is selected from the group consisting of peptides, polypeptides, proteins and macromolecules having a molecular weight of at least about 300 daltons.
Claim 18
Dependent Claim
42 words
The method of claim 11, wherein the beneficial agent is selected from the group consisting of insulin, growth hormones, buserelin, leuprolide, LHRH, metoclopramide, fentanyl, lidocaine, ketoprofen, sufentanil, terbutaline, droperidol, heparin, interferon, scopolamine, testosterone, gonadorelin, ciclopirox olamine, buspirone, calcitonin, cromolyn sodium, and midazolam.
Claim 19
Dependent Claim
13 words
The method of claim 12, wherein the skin permeation enhancer comprises a surfactant.
References Cited (Backward Citations)
US3991755A
Cited
US4767401A
Cited
US4141359A
Cited
US4250878A
Cited
US4391278A
Cited
US4398545A
Cited
US4382529A
Cited
US4474570A
Cited
US4919648A
Cited
US4764164A
Cited
US4702732A
Cited
US4809707A
Cited
US4867982A
Cited
US4722726A
Cited
US4786277A
Cited
US4878892A
Cited
US4940456A
Cited
US4931046A
Cited
US4942883A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-12-01 | 1996-06-01 | 1996-12-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-12-01 | 2000-06-01 | 2000-12-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-12-01 | 2004-06-01 | 2004-12-01 | $7700.00 | Window Closed / Lapsed |